Key Takeaways AbbVie posted Q2 EPS of $2.97 on $15.42 billion in revenue, beating estimates and prior company guidance.Strong sales of Rinvoq, Skyrizi, Vraylar and newer drugs offset Humira and Imbruvica declines.ABBV raised full-year 2025 EPS guidance to $11.88-$12.08, up from its prior $11.67-$11.87 range.AbbVie Inc. (ABBV) reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The reported figure also exceeded the company’s guidance of $2.84-$2.88 issued ear ...

Key Takeaways AbbVie will report Q2 earnings on July 31, with estimates at $15.07 billion for revenues and $2.89 for EPS.Skyrizi and Rinvoq are expected to drive growth, offsetting Humira sales erosion.Neuroscience sales strength contrasts with softness in aesthetics amid Botox and Juvederm slowdown.AbbVie (ABBV) is set to report second-quarter 2025 earnings on July 31, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $15.07 billion and $2.89 per share, ...

公司业务表现 - 公司在神经科学领域占据领导地位 拥有肉毒杆菌治疗药物Botox Therapeutic和抑郁症药物Vraylar等重磅产品 [1] - 神经科学业务占公司第一季度收入的17% 同比增长16% [1] - 预计2025年第二季度神经科学业务销售额达25亿美元 同比增长15% [2][10] - 新推出的帕金森病药物Vyalev在美国市场贡献有限 主要收入来自国际市场 [3][10] 产品线分析 - 肉毒杆菌治疗药物Botox Therapeutic和抑郁症药物Vraylar是主要增长驱动力 [2] - 偏头痛口服药Ubrelvy和Qulipta可能因市场份额提升而受益 [2] - 免疫学业务仍是投资者关注焦点 包含Humira、Rinvoq和Skyrizi三款旗舰药物 [4] 行业竞争格局 - 主要竞争对手包括Biogen和强生 [5] - Biogen超过一半收入来自神经科学疗法 拥有阿尔茨海默病治疗药物Leqembi和产后抑郁口服药Zurzuvae [6] - 强生拥有抗抑郁鼻喷雾Spravato和抗精神病药物Invega Sustenna 并通过收购获得抗抑郁药Caplyta [8] 财务与估值 - 公司股价年内表现优于行业平均水平 [9] - 当前市盈率为14.06倍 略低于行业平均14.60倍 [12] - 2025年每股收益预估从12.32美元下调至11.98美元 2026年预估从14.06美元上调至14.08美元 [13]